In Case You Missed It
5 Things You Must Know Before the Market Opens
Jim Cramer's Daily Booyah
Winners & Losers
Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.
The company's shares were falling again on Wednesday, this time on the news that its initial application for an anti-asthma generic had been rejected by the FDA.
The deal helps the company manage its $31 billion debt load, sending the shares up nearly 4% midday Wednesday.
The company could be gearing up for multiple challenges on the D.C. front, analysts say.
The company specializes in 'neural lace,' an appendage that attaches to the brain, allowing a way for the brain to interact with devices
Mike Pearson is alleging that Valeant has refused to pay him for the three million shares he is owed.
The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.
Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.
Investors weren't completely distracted by the Affordable Care Act debate.
These big stocks are teetering on the edge of breakdown territory.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.